Drug Profile
AZD 3409
Alternative Names: AZD-3409; EBP-921; ZD-3409Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Eiger BioPharmaceuticals
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis D; Solid tumours
Most Recent Events
- 22 Dec 2015 Discontinued - Phase-I for Hepatitis D in USA (PO)
- 09 Jun 2005 Data presented at the 100th Annual Meeting of the American Urological Association (AUA-2005) have been added to the adverse events and Cancer pharmacodynamics sections
- 14 Dec 2004 A clinical study has been added to the Cancer pharmacodynamics section